However, patients 65 years or older (< 0.001), with longer diabetes duration (p = 0.046), and with longer hypertension duration (p < 0.001) appear to benefit more from SGLT2-i and RAS-i combination therapy (eFig. 2B). Here, SLC5A2 is linked to hypertensive disorder.